(Q36047171)

11 August 2017

1 reference

title

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia (English)

1 reference

11 August 2017

0 references

1 reference

Ruibao Ren

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

11 August 2017

published in

Nature Reviews Cancer

1 reference

11 August 2017

volume

5

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

172-183

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1567

11 August 2017

exact match

0 references

cites work

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

Chronic myeloid leukemia: current treatment options

31 March 2020

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

31 March 2020

1 reference

Chronic myelogenous leukemia

31 March 2020

1 reference

Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction

31 March 2020

1 reference

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

31 March 2020

1 reference

Minimal residual disease in chronic myeloid leukemia

31 March 2020

1 reference

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Resistance to imatinib (Glivec): update on clinical mechanisms

31 March 2020

1 reference

Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases

31 March 2020

1 reference

How do Abl family kinases regulate cell shape and movement?

31 March 2020

1 reference

Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations

31 March 2020

1 reference

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

31 March 2020

1 reference

Essential roles for the Abl and Arg tyrosine kinases in neurulation

31 March 2020

1 reference

Increased neutrophil respiratory burst in bcr-null mutants

31 March 2020

1 reference

The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model

31 March 2020

1 reference

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

31 March 2020

1 reference

A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector

31 March 2020

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

31 March 2020

1 reference

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

31 March 2020

1 reference

High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells

31 March 2020

1 reference

Retroviral expression in embryonic stem cells and hematopoietic stem cells

31 March 2020

1 reference

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

31 March 2020

1 reference

Humanbcr-abl gene has a lethal effect on embryogenesis

31 March 2020

1 reference

Acute leukaemia in bcr/abl transgenic mice

31 March 2020

1 reference

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

31 March 2020

1 reference

Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome

31 March 2020

1 reference

Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

31 March 2020

1 reference

The biology of chronic myeloid leukemia

31 March 2020

1 reference

NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia

31 March 2020

1 reference

Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature.

31 March 2020

1 reference

Core-binding factors in hematopoiesis and immune function

31 March 2020

1 reference

The transcription factor Evi-1.

31 March 2020

1 reference

Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML

31 March 2020

1 reference

Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia

31 March 2020

1 reference

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

31 March 2020

1 reference

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

31 March 2020

1 reference

Modeling the dosage effect of oncogenes in leukemogenesis

31 March 2020

1 reference

Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy

31 March 2020

1 reference

Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells

31 March 2020

1 reference

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

31 March 2020

1 reference

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl

31 March 2020

1 reference

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

31 March 2020

1 reference

Autoinhibition of Bcr-Abl through its SH3 domain

31 March 2020

1 reference

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

31 March 2020

1 reference

Critical role for Gab2 in transformation by BCR/ABL

31 March 2020

1 reference

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

31 March 2020

1 reference

The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype

31 March 2020

1 reference

The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

31 March 2020

1 reference

Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation

31 March 2020

1 reference

Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development

31 March 2020

1 reference

Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis

31 March 2020

1 reference

Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis

31 March 2020

1 reference

The BCR-ABL story: bench to bedside and back

31 March 2020

1 reference

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

31 March 2020

1 reference

c-CBL is not required for leukemia induction by Bcr-Abl in mice

31 March 2020

1 reference

Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.

31 March 2020

1 reference

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

31 March 2020

1 reference

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

31 March 2020

1 reference

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

31 March 2020

1 reference

PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome

31 March 2020

1 reference

The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling

31 March 2020

1 reference

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder

31 March 2020

1 reference

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease

31 March 2020

1 reference

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

31 March 2020

1 reference

ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages.

31 March 2020

1 reference

Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder

31 March 2020

1 reference

JunB is essential for mammalian placentation

31 March 2020

1 reference

Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage

31 March 2020

1 reference

JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells.

31 March 2020

1 reference

Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea

31 March 2020

1 reference

JunB gene expression is inactivated by methylation in chronic myeloid leukemia

31 March 2020

1 reference

Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice

31 March 2020

1 reference

Does Rap1 deserve a bad Rap?

31 March 2020

1 reference

BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells.

31 March 2020

1 reference

Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span

31 March 2020

1 reference

BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis

31 March 2020

1 reference

Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia

31 March 2020

1 reference

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

31 March 2020

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

31 March 2020

1 reference

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

31 March 2020

1 reference

BCR-ABL-induced adhesion defects are tyrosine kinase-independent

31 March 2020

1 reference

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

31 March 2020

1 reference

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

31 March 2020

1 reference

Chronic myeloid leukemia-still a few questions

31 March 2020

1 reference

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

31 March 2020

1 reference

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

31 March 2020

1 reference

Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data

31 March 2020

1 reference

Structural basis for the autoinhibition of c-Abl tyrosine kinase

31 March 2020

1 reference

Variation on an Src-like theme

31 March 2020

1 reference

A myristoyl/phosphotyrosine switch regulates c-Abl

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1567

1 reference

11 August 2017

1 reference